To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The company will also share results in two additional posters for deuruxolitinib
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
NMC to continue its efforts to improve and enhance the quality of medical education in the country
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Subscribe To Our Newsletter & Stay Updated
